Sugi Predict

Sugi Predict / Compounds / SCHEMBL19084324

SCHEMBL19084324

SCHEMBL19084324

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](CN=[N+]=[N-])Cc1ccc(NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CCC(=O)N2CCC(C(=O)O)CC2)C(C)C)cc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.41
▸ FOLH1 Q04609 3/20 0.39
▸ TTR P02766 2/20 0.35
▸ SSTR2 P30874 2/20 0.34
▸ CTSD P07339 1/20 0.31
▸ CTSE P14091 1/20 0.31
▸ BACE1 P56817 1/20 0.31
▸ NECTIN4 Q96NY8 1/20 0.30
▸ OXTR P30559 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17987725 0.99 CYP3A4 (0.40) CYP3A4FOLH1TTRSSTR2CTSD
SCHEMBL20800166 0.92 CYP3A4 (0.48) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL17987755 0.92 CYP3A4 (0.48) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL23586811 0.89 CYP3A4 (0.38) CYP3A4FOLH1TTRSSTR2CTSD
SCHEMBL20846024 0.89 CYP3A4 (0.40) CYP3A4FOLH1TTRSSTR2CTSD
SCHEMBL20800164 0.88 CYP3A4 (0.47) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL17987724 0.88 CYP3A4 (0.47) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL20846103 0.88 CYP3A4 (0.40) CYP3A4FOLH1TTRSSTR2CTSD
SCHEMBL24465502 0.88 CYP3A4 (0.44) CYP3A4FOLH1TTRSSTR2NECTIN4
SCHEMBL24193297 0.87 CYP3A4 (0.52) CYP3A4FOLH1TTRSSTR2NECTIN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170190736-A1 Antibody Drug Conjugates SORRENTO THERAPEUTICS, INC. (US) 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190736-A1 Antibody Drug Conjugates STT3B, STT3A, HSD17B14 CYP3A4 49/4885FOLH1 392/4885TTR 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.